Compare · LH vs OSA
LH vs OSA
Side-by-side comparison of Labcorp Holdings Inc. (LH) and ProSomnus Inc. (OSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and OSA operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $25.85B.
- LH has hit the wire 7 times in the past 4 weeks while OSA has been quiet.
- LH has more recent analyst coverage (25 ratings vs 0 for OSA).
- Company
- Labcorp Holdings Inc.
- ProSomnus Inc.
- Price
- $263.82-0.44%
- $0.50-15.25%
- Market cap
- $25.85B
- -
- 1M return
- -0.86%
- -
- 1Y return
- +14.64%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H
Latest OSA
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)
- SEC Form 25-NSE filed by ProSomnus Inc.
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- ProSomnus Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by ProSomnus Inc.
- ProSomnus Q4 Sales $7.84M Beat $7.37M Estimate
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- ProSomnus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits